在治疗结束时，蛋白酶体水平升高患者的中位生存期是30.2个月。蛋白酶体水平恢复正常的患者没有观察到终点事件。
Median survival at the end of treatment was 30.2 months in patients with elevated levels. This point was not reached in patients with normalized levels.
目前，医学教科书估计的晚期乳腺癌中位生存期为2年至3年。
Currently, medical textbooks estimate the median survival for advanced breast cancer to be 2 to 3 years.
血浆中egfr外显子19删除患者的中位生存期要明显好于那些存在L 858r变异患者(32个月相对14个月)。
Median survival time for patients with an EGFR exon 19 deletion in serum was also substantially higher than in those with L858R mutations (32 months vs 14 months).
接受氟尿嘧啶联合亚叶酸方案治疗或是吉西他滨方案治疗患者的中位生存期分别为23.0个月及23.6个月。
Median survival for patients treated with fluorouracil plus folinic acid was 23.0 months and for patients treated with gemcitabine was 23.6 months.
但中位总生存期，次要观察终点，联合组为20.5个月，而单药治疗组为20.6个月。
But median overall survival, a secondary end point, was 20.5 months in the combination group and 20.6 months in the monotherapy group.
这项试验中，31名患者被纳入研究，5名患者反应良好，疾病稳定，中位生存期为4.4个月。
In this study with 31 patients enrolled thus far, the best response was stable disease in 5 patients with a median OS of 4.4 months.
结论TP方案治疗晚期鼻咽癌肝、肺转移疗效明显优于DF方案，中位生存期TP组也高于DF组。
Conclusion The treatment effect and median survival in TP regiment group were apparently higher than those in DF regiment group.
对124名法国患者的进一步研究提示，运用该模型，认为无风险的患者中位生存期为378天，有风险的只有90天。
Study of a further 124 French patients showed that those deemed at good risk using the model, had a median survival of 378 days, compared to 90 days in the poor risk group.
中位无进展生存期为6个月。
三种手术方式的中位生存期分别为5,16,28个月。
The median survival time was 5, 16, 28 months, respectively.
吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。
The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.
结论：我们对边缘区淋巴瘤的研究是已报道的研究中规模最大的之一，结论是边缘区淋巴瘤总体预后良好，中位总生存期超过19年。
Conclusions: In our MZL series, one of the largest reported, prognosis of MZL is good with a median OS of over 19 years.
中位生存期为11个月。
另外，对5例化疗患者和10例非化疗患者(均为高危组MDS患者)进行中位生存期和生存率比较。
Besides, compare median survival time with survival rate for 5 cases of chemotherapy group and 10 cases of non-chemotherapy group (the high-risk group of MDS patients). Results: 1.
腹膜恶性间皮瘤预后较差，综合治疗后中位生存期约1.5年。
The prognosis of PMM is bad. The meso life span is about 1.5 years after combined therapy.
生存者存活期均超过8个月，中位生存期1 6月，生活质量改善。
Twenty-five patients survived over 8 months with the median survival time 16 months and life quality were improved.
结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
所有患者中位随访时间35.8个月，80例出现复发或转移，40例死亡，中位生存期未达到，中位无疾病生存期（DFS）为24.1个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
肝切除术、胆管取癌栓及胆道引流术病人术后生存时间为5 ~ 4 6个月，中位生存期为2 3 5个月。
After hepatectomy with embolectomy and biliary duct drainage, the survival time was 5-46 months and the survival median time was 23.5 months.
术后替莫唑胺化疗组中位无进展生存期较单纯手术组显著延长（P<0.05），其余各组之间差异无统计学意义。
PFS of temozolomide chemotherapy group is higher than that of single operation group(P<0.05), and there were no significant differences of PFS between the other groups.
术后替莫唑胺化疗组中位无进展生存期较单纯手术组显著延长（P<0.05），其余各组之间差异无统计学意义。
PFS of temozolomide chemotherapy group is higher than that of single operation group(P<0.05), and there were no significant differences of PFS between the other groups.
应用推荐